deeper dive pharmedium
trim ep pharmedium asset
light recent
develop relat pharmedium asset lower ep
vs street view trim ep
vs street view recal acquir pharmedium lead us
provid compound steril prepar csp acut care hospit
approxim bln cash late ttm ebitda time deal
management discuss last quarter run issu fda largest
compound facil suggest resolut would occur march qtr
howev new issu evolv anoth facil ceas desist order late
feb state ca tx facil still clariti yet origin
fda issu relat memphi tn facil repres half total volum
frame pharmedium oper within overal help frame
impact pharmedium oper overal provid stand-alone
pharmedium annual incom period figur pg note
base analysi prior compani disclosur estim pharmedium
may contribut mln ebitda ep overal
essenti repres period prior issu pharmedium
describ detail pg note instead
pharmedium grow calendar estim ebitda may declin
mln calendar ep contribut also declin
risk thesi valuat given risk issu memphi tn
sugarland tx facil within pharmedium facil could impact abc
perform ep beyond march quarter still current guidanc
compani lower pt lower price-to-earnings
lower calendar ep view price-to-earnings still repres
slight premium peer account abc larger specialti drug
distribut oper well walgreen long-term acquisit option
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
equal weight compani
gain share via largest custom walgreen
compani continu face headwind
throughout relat gener price deflat
believ persist hamper ep growth
upsid case see modest multipl expans
gener price deflat come better fear
would lead multipl ep
downsid case see continu persist
gener deflat continu problem
pharmedium bring compani peer
group
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
deeper dive pharmedium
announc acquisit pharmedium octob approxim bln
cash pharmedium lead nation provid compound steril prepar
csp acut care hospit us market primari function busi
combin mix pharmaceut creat drug therapi custom meet specif
hospit physician clinic need formul otherwis commerci
avail around time acquisit disclos pharmedium
prepar provid sku meet requir roughli acut care
hospit locat across state provid pharmedium stand-alone
compani report barclay estim
pharmedium ex one-tim addback expens excl oper net ep ep barclay corp
analysi pharmedium facil
fda state board pharmaci inspect serv entir us
feder drug qualiti secur act dqsa call enhanc regul csp
creat new categori provid csp allow facil voluntarili
regist fda pharmedium compound facil
regist facil pharmedium compound fda-approv allow
drug finish dosag form use fda-approv diluent fda-clear contain
hospit outsourc servic pharmedium meet specif hospit
physician clinic need effici safe manner often addit servic
featur enhanc label extend expir date support
appropri studi exceed hospit pharmaci accomplish
recent news regard pharmedium largest facil tn
press pharmedium news right current closur memphi
facil approxim half entiti product volum occur facil
voluntarili close decemb deal issu cite letter fda
ensur facil would complianc fda regul
compound polici commun
decemb quarter
earn call expect facil re-open end term
cost relat closur re-open facil indic would
like mln neg impact oper incom pharmedium
outsourc facil inspect fda begin late calendar
carri earli result inspect voluntarili suspend
oper memphi facil memphi largest product facil
highli autom engag on-going dialogu fda implement
correct action taken confirm clear pathway full complianc
facil management previous optimist memphi oper would restart
earli januari instead revis expect re-open later march quarter
newer issu pop ca relat tx facil
separ memphi facil state california issu order ceas
desist compani sugarland texa facil order effect day
time issuanc februari given time facil ship
california end march link ceas desist order management yet
opportun comment new ca/tx develop sinc surfac
invest conclus
order help provid color investor potenti impact pharmedium
issu overal built stand-alone pharmedium annual incom statement
period figur show contribut given
final week march quarter still updat combin
seemingli cautiou tone management around pharmedium barclay healthcar
confer two week ago take conserv stanc lower
ep vs street view trim ep
vs street view also lower pt
lower price-to-earnings lower calendar ep view
await see management still expect ramp product exit year
full product beyond given high demand outsourc csp model
pharmedium resum revenu ebitda growth
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
